Profound molecular response with ponatinib in chronic phase of chronic myeloid leukemia with resistance to imatinib and dasatinib: Case report and review of the literature
DOI:
https://doi.org/10.20453/rmh.v33i2.4247Keywords:
BCR-ABL positive chronic myelogenous leukemia, Protein Tyrosine Kinases, hiladelphia ChromosomeAbstract
We report the case of a woman who at the age of 54 years was diagnosed with chronic myeloid leukemia in chronic phase; she began treatment with a first-generation tyrosine kinase inhibitor, and evidenced failure due to the absence of a hematological and cytogenetic response. Despite changing treatment to a second-generation tyrosine kinase inhibitor (dasatinib), it was not possible to achieve optimal levels of response, documenting positivity for the T315I mutation in the ABL domain of the deregulated BCR/ABL tyrosine kinase, compared to ponatinib, the only drug that shows activity. After starting treatment with ponatinib, optimal levels of cytogenetic and molecular response were evidenced, as well as an adequate quality of life for the patient.
References
Goldman JM, Melo JV. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 2003; 349(15):1451-64.
Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net Blood. 2006; 108(6):1809-20.
Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016; 34(24):2851-7.
Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015; 2(5):e186-93.
Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016; 30(8):1648-71.
Kropf P, Barnes G, Tang B, Pathak A, Issa J-P. Burden of tyrosine kinase inhibitor failure in patients with chronic myeloid leukemia. J Leuk. 2014; 3(1): 1-6.
Patel AB, O’Hare T, Deininger MW. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. Hematol Oncol Clin North Am. 2017; 31(4):589-612.
Navarro J, Carracedo C, Samanez C, et al. Uso de recursos sanitarios para tratar la leucemia mieloide crónica en Perú. Acta Méd Peruana. 2010;27:53-61.
Moreno LK. Aspectos epidemiológicos y características clínico-hematológicas en pacientes diagnosticados con LMC (Leucemia Mieloide Crónica) atendidos en el INEN (Instituto Nacional de Enfermedades Neoplásicas) durante el período 2000-2009. Lima: Universidad Nacional Mayor de San Marcos; 2015.
Howlader N, Krapcho M, Miller D, et al. SEER Cancer Statistics Review (CSR) 1975-2018. Bethesda: National Cancer Institute; 2021. (Citado el 28 de mayo del 2021). Disponible en: https://seer.cancer.gov/csr/1975_2018/sections.html#content.
Goldman JM. Ponatinib for chronic myeloid leukemia. N Engl J Med. 2012; 367(22):2148-9.
Gozgit JM, Schrock A, Chen T-H, Clackson T, Rivera VM. Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants. Blood. 2013; 122(21):3992.
Rivera V, Branford S, Nicolini F-E, et al. A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients. Blood. 2015; 126:2790.
Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias. N Engl J Med. 2012; 367(22):2075-88.
Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias. N Engl J Med. 2013; 369(19):1783-96.
O’Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res. 2011; 17(2):212-21.
Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018; 17(1):49.
Zhou T, Commodore L, Huang WS, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des. 2011; 77(1):1-11.
European Medicines Agency. Iclusig (ponatinib) Información general sobre Iclusig y sobre los motivos por los que se autoriza su uso en la UE. Amsterdam: The Agency; 2018. (Citado el 28 de mayo del 2021). Disponible en: https://www.ema.europa.eu/en/documents/overview/iclusig-epar-summary-public_es.pdf.
Drugs.com. FDA Approves Iclusig. New York; Drugs.com; 2021. (Citado el 28 de mayo del 2021). Disponible en: https://www.drugs.com/support/contact.html.
Januzzi JL, Garasic J, Kasner S, et al. An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia. J Clin Oncol. 2020; 38(15_suppl):7550.
Cortes JE, Lomaia E, Turkina A, et al. Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses. J Clin Oncol. 2020; 38(15_suppl):7502.
Takeda Pharmaceutical Company. U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML. Tokio: Takeda; 2020. (Citado el 28 de mayo del 2021). Disponible en: https://www.takeda.com/newsroom/newsreleases/2020/u.s.-fda-approves-supplemental-new-drug-application-for-takedas-iclusig-ponatinib-for-adult-patients-with-resistant-or-intolerant-chronic-phase-cml/.
Deininger MW, Shah NP, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020; 18(10):1385-415.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-84.
Downloads
Published
How to Cite
Issue
Section
License
Authors assign their rights to the RMH so that may disseminate the article through the means at their disposal. The journal will provide forms of affidavit of authorship and authorization for the publication of the article, which shall be submitted with the manuscript. Authors retain the right to share, copy, distribute, perform and publicly communicate their article, or part of it, mentioning the original publication in the journal.
